Cannabics’ team of scientists has developed a high throughput screening system which is specifically designed to give personalized antitumor treatments to cancer patients.
In this proprietary system, biopsies are treated, in-vitro, with innumerous plant extract combinations and the antitumor effects are screened and calculated.
The results could enable cancer patients to receive cannabinoid based therapy with a potential of reducing their tumors. Cannabics Pharmaceuticals plans to complete the development of this novel and sophisticated technology and license it by the end of 2016.
Dr. Eyal Ballan, Chief Scientist of the company said," Cannabinoids are known for their antitumor properties, and this natural personalized therapy could be highly effective and without side effects, thus benefiting millions of patients worldwide."